{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T04:35:26Z","timestamp":1790224526520,"version":"4.1.0"},"reference-count":23,"publisher":"BMJ","issue":"7","license":[{"start":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T00:00:00Z","timestamp":1753228800000},"content-version":"unspecified","delay-in-days":22,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2025,7,8]]},"published-print":{"date-parts":[[2025,7]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>A relationship between long-term metformin use and vitamin B12 deficiency has been long discussed in the literature. Nonetheless, prior to 2022, there was no official guidance. In June 2022, the Medicines and Healthcare products Regulatory Agency (MHRA) published advice, stating that low vitamin B12 is now considered to be a common side effect. It advises checking levels in patients with symptoms of B12 deficiency, as well as monitoring those at risk of B12 deficiency.<\/jats:p>\n                    <jats:p>Despite efforts to promote evidence-based practice, there is still a gap in the translation of research findings into policies and clinical practice. The above research has been shared widely in the academic and specialist diabetes literature over a prolonged period. The purpose of the scoping review is to explore what evidence is available regarding clinicians\u2019 awareness of the association between metformin use and vitamin B12 deficiency in patients with type 2 diabetes mellitus, how this evidence is implemented into frontline clinical practice and what screening processes are recommended or exist.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and analysis<\/jats:title>\n                    <jats:p>This is a protocol for a scoping review to be guided by the Joanna Briggs Institute (JBI) methodology for scoping reviews 20. The databases to be searched will include MEDLINE (accessed via PubMed), British Nursing Index, Google Scholar, Cochrane, Embase, Web of Science and Cumulative Index to Nursing and Allied Health Literature (CINAHL) (accessed via EBSCO), alongside searching for grey literature such as Electronic Theses Online Service (EThOS), DART European and Kings College London Research Portal. Titles and abstracts of articles will be reviewed by the authors. If articles are representative of the inclusion criteria, the articles will go through a full-text review by the authors. The results of the search and study inclusion\/exclusion process will be reported and presented in a Preferred Reporting Items for Systematic Reviews and Meta-analyses flow diagram. Data will be extracted from papers, using the recommended JBI data extraction tool. The search will commence in August 2025, and the review is expected to be completed by November 2025.<\/jats:p>\n                    <jats:p>The search will commence in August 2025, and the review is expected to be completed by November 2025.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Ethics and dissemination<\/jats:title>\n                    <jats:p>As this is a scoping review protocol that did not involve any human participants, human data or human tissue, no ethical approval was required. Our dissemination strategy includes peer review publication, presentation at conferences and with relevant stakeholders.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2025-101016","type":"journal-article","created":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T04:10:39Z","timestamp":1753243839000},"page":"e101016","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":7,"title":["Vitamin B12 deficiency in long-term metformin use and clinician awareness: a scoping review protocol"],"prefix":"10.1136","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-9987-4052","authenticated-orcid":false,"given":"Ian","family":"Parsonage","sequence":"first","affiliation":[{"name":"Health Sciences, University of Bath, Bath, England, UK"},{"name":"Compass House Medical Centres, Brixham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Wainwright","sequence":"additional","affiliation":[{"name":"Health Sciences, University of Bath, Bath, England, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julian","family":"Barratt","sequence":"additional","affiliation":[{"name":"Aston University, Birmingham, England, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,7,22]]},"reference":[{"key":"2025121602481684000_15.7.e101016.1","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2019.107843"},{"key":"2025121602481684000_15.7.e101016.2","unstructured":"Statista . Leading 10 drugs used in the treatment of diabetes in England in 2022, by number of items. 2023. Available: https:\/\/www.statista.com\/statistics\/377865\/top-ten-drugs-used-in-diabetes-by-items-in-england"},{"key":"2025121602481684000_15.7.e101016.3","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2015-010210","article-title":"Trends in incidence, prevalence and prescribing in type 2 diabetes mellitus between 2000 and 2013 in primary care: a retrospective cohort study","volume":"6","author":"Sharma","year":"2016","journal-title":"BMJ Open"},{"key":"2025121602481684000_15.7.e101016.4","doi-asserted-by":"crossref","first-page":"2046","DOI":"10.3390\/nu14102046","article-title":"Vitamin B12 Deficiency in Patients with Diabetes on Metformin: Arab Countries","volume":"14","author":"Alhaji","year":"2022","journal-title":"Nutrients"},{"key":"2025121602481684000_15.7.e101016.5","unstructured":"National Institute for Clinical Excellence (NICE) . Type 2 diabetes in adults: management. 2022. Available: https:\/\/www.nice.org.uk\/guidance\/ng28"},{"key":"2025121602481684000_15.7.e101016.6","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.2.5763.685"},{"key":"2025121602481684000_15.7.e101016.7","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.c2181","article-title":"Long term treatment with metformin in patients with type 2 diabetes and risk of vitamin B-12 deficiency: randomised placebo controlled trial","volume":"340","author":"de Jager","year":"2010","journal-title":"BMJ"},{"key":"2025121602481684000_15.7.e101016.8","doi-asserted-by":"publisher","DOI":"10.1007\/BF00427979"},{"key":"2025121602481684000_15.7.e101016.9","doi-asserted-by":"publisher","DOI":"10.2337\/dc21-S002"},{"key":"2025121602481684000_15.7.e101016.10","doi-asserted-by":"crossref","first-page":"916","DOI":"10.4239\/wjd.v12.i7.916","article-title":"Long-term metformin therapy and vitamin B12 deficiency: An association to bear in mind","volume":"12","author":"Infante","year":"2021","journal-title":"World J Diabetes"},{"key":"2025121602481684000_15.7.e101016.11","unstructured":"Medicines and Healthcare products Regulatory Authority (MHRA) . Metformin and reduced vitamin b12 levels: new advice for monitoring patients at risk. 2022. Available: https:\/\/www.gov.uk\/drug-safety-update\/metformin-and-reduced-vitamin-b12-levels-new-advice-for-monitoring-patients-at-risk"},{"key":"2025121602481684000_15.7.e101016.12","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1001\/jamainternmed.2019.0294","article-title":"Comparative Analysis of Medicines Safety Advisories Released by Australia, Canada, the United States, and the United Kingdom","volume":"179","author":"Perry","year":"2019","journal-title":"JAMA Intern Med"},{"key":"2025121602481684000_15.7.e101016.13","unstructured":"Clinical knowledge summaries. diabetes - type 2: metformin. 2023. Available: https:\/\/cks.nice.org.uk\/topics\/diabetes-type-2\/prescribing-information\/metformin\/#:~:text=The%20risk%20of%20low%20vitamin,disorders%20such%20as%20Crohn\u2019s%20disease"},{"key":"2025121602481684000_15.7.e101016.14","doi-asserted-by":"publisher","DOI":"10.1136\/ebn.8.2.36"},{"key":"2025121602481684000_15.7.e101016.15","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1146\/annurev-pharmtox-010818-021348","article-title":"Moving from the Trial to the Real World: Improving Medication Adherence Using Insights of Implementation Science","volume":"59","author":"Zullig","year":"2019","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"2025121602481684000_15.7.e101016.16","unstructured":"National Institute for Health and Care Research (NIHR) . Implementation science. 2022. Available: https:\/\/arc-sl.nihr.ac.uk\/research-and-implementation\/our-research-methods\/implementation-science"},{"key":"2025121602481684000_15.7.e101016.17","doi-asserted-by":"publisher","DOI":"10.1097\/XEB.0000000000000050"},{"key":"2025121602481684000_15.7.e101016.18","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2014.03.013"},{"key":"2025121602481684000_15.7.e101016.19","doi-asserted-by":"crossref","DOI":"10.1186\/s12874-018-0611-x","article-title":"Systematic review or scoping review? Guidance for authors when choosing between a systematic or scoping review approach","volume":"18","author":"Munn","year":"2018","journal-title":"BMC Med Res Methodol"},{"key":"2025121602481684000_15.7.e101016.20","unstructured":"Joanna Briggs Institute . Checklist for systematic reviews and research syntheses. 2017. Available: https:\/\/joannabriggs.org\/ebp\/critical_appraisal_tools"},{"key":"2025121602481684000_15.7.e101016.21","doi-asserted-by":"publisher","DOI":"10.7326\/M18-0850"},{"key":"2025121602481684000_15.7.e101016.22","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"2025121602481684000_15.7.e101016.23","doi-asserted-by":"publisher","DOI":"10.1080\/1364557032000119616"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2025-101016","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T10:48:27Z","timestamp":1765882107000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2025-101016"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":23,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2025,7,22]]},"published-print":{"date-parts":[[2025,7]]}},"alternative-id":["10.1136\/bmjopen-2025-101016"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2025-101016","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7]]}}}